Safe and Timely Antithrombotic Removal (STAR) Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCytoSorbents, Inc
About this trial
This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
CytoSorb utilization for antithrombotic removal
Informed consent for prospective registry participation
Disqualifiers
None
Trial population
All patients undergoing invasive management, including surgery, who receive CytoSorb therapy for antithrombotic removal as part of their routine clinical care can be included in this registry
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
CytoSorb
DeviceSorbent hemoperfusion system
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Bleeding complications including requirements for transfusions and other blood products
Time frame
Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov